DERM - デルミラ (Dermira Inc.) デルミラ



symbol DERM
会社名 Dermira Inc (デルミラ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ダーミラ(Dermira Inc.)はバイオ医薬品会社である。同社は乾癬、多汗症、アクネ等の皮膚症状を治療する皮膚病学の治療ソリューションの開発に従事する。同社のポートフォリオはセルトリズマブ・ペゴルのCimzia、グリコピロニウム・トシラート、olumacostat glasaretilという3つの後期製品候補を含む。Cimziaは注射性生物学的腫瘍壊死因子(TNF)アルファ阻害薬であり、リューマチ性関節炎、乾癬性関節炎、強直性せきつい炎、クローン病を含む各種炎症性疾患の治療のために認可・販売される。グリコピロニウム・トシラートは原発性腋窩多汗症の治療向けの局所適用小分子抗コリン作用薬である。olumacostat glasaretilはアクネの治療用局所適用皮脂生成をターゲットとする小分子である。   デルミラは米国のバイオ医薬品会社。皮膚科用製品の開発と製造に注力する。新薬候補には中度・重度の尋常性乾癬症治療用モノクロナ―ル抗体「シムジア(セルトリズマブペゴ―ル)」、多汗症治療用の小分子抗コロン作用薬DRM04、にきび治療用皮脂抑制剤DRM01がある。本社はカリフォルニア州。   Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith in 2010 and is headquartered in Menlo Park, CA.
本社所在地 275 Middlefield Road Suite 150 Menlo Park CA 94025 USA
代表者氏名 Thomas G. Wiggans トーマス・G・ウィガンズ
代表者役職名 Chairman of the Board Chief Executive Officer Co-Founder
電話番号 +1 650-421-7200
設立年月日 40391
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 162人
EBITDA EBITDA(百万ドル) -179.77200
終値(lastsale) 11.92
時価総額(marketcap) 500954568.8
時価総額 時価総額(百万ドル) 508.09910
売上高 売上高(百万ドル) 41.78800
企業価値(EV) 企業価値(EV)(百万ドル) 351.47710
当期純利益 当期純利益(百万ドル) -318.37200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Dermira Inc revenues increased from $2.1M to $39.4M. Net loss increased 22% to $83.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and Administrative increase from $19M to $61.7M (expense) Interest Expense increase from $1.3M to $9M (expense).



   Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates  2020/01/17 07:11:00 Zacks Investment Research
Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.
   Bragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Dermira, Primo Water, Hexcel, and Pope Resources on behalf of Stockholders and Encourages Investors to Contact the Firm  2020/01/15 18:19:00 PR Newswire
NEW YORK, Jan. 15, 2020 /PRNewswire/ -- Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Dermira, Inc. (NASDAQ: DERM), Primo Water Corporation (NASDAQ: PRMW), Hexcel Corporation (NYSE: HXL), and Pope Resources, A…
   Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate  2020/01/13 08:08:00 Zacks Investment Research
Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.
   SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of DERMIRA, INC. - DERM  2020/01/10 18:23:00 PR Newswire
NEW YORK, Jan. 10, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Dermira, Inc. ("Dermira" or the "Company") (Nasdaq: DERM) relating…
   Eli Lilly Reports Deal To Buy Dermira For $1.1B  2020/01/10 12:28:30 Benzinga
Eli Lilly (NYSE: LLY ) announced Friday it will acquire Dermira, Inc. (NASDAQ: DERM ) for $18.75 per share, around $1.1 billion, in an all-cash transaction. Dermira is a biopharmaceutical company developing new therapies for chronic skin conditions. "People suffering from moderate-to-severe atopic dermatitis have significant unmet treatment needs, and we are excited about the potential that lebrikizumab has to help these patients," said Patrik Jonsson, Lilly senior vice president and president of Lilly Bio-Medicines. "The acquisition of Dermira is consistent with … Full story available on

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デルミラ DERM Dermira Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)